Search Results

Peptide-Based Dual HIV and Coronavirus Entry Inhibitors.

• Authors : Wang H; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China.; Wang C

Subjects: Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/pharmacology ; Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/therapeutic use ; Coronavirus*

• Source: Advances in experimental medicine and biology [Adv Exp Med Biol] 2022; Vol. 1366, pp. 87-100.Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 0121103 Publication Model: Print Cited Medium: Print ISSN:

Record details

Development of Protein-Protein Interaction Inhibitors for the Treatment of Infectious Diseases.

• Authors : Voter AF; University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.; Keck JL

Subjects: Anti-Bacterial Agents/Anti-Bacterial Agents/Anti-Bacterial Agents/*pharmacology ; Antiviral Agents/Antiviral Agents/Antiviral Agents/*pharmacology ; Communicable Diseases/Communicable Diseases/Communicable Diseases/*drug therapy

• Source: Advances in protein chemistry and structural biology [Adv Protein Chem Struct Biol] 2018; Vol. 111, pp. 197-222. Date of Electronic Publication: 2017 Aug 24.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101497281 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Inhibition of virus entry: an antiviral mechanism of emerging prominence.

• Authors : Koszalka GW; Meanwell NA

Subjects: Antiviral Agents/Antiviral Agents/Antiviral Agents/*pharmacology ; HIV/HIV/HIV/*drug effects ; HIV Fusion Inhibitors/HIV Fusion Inhibitors/HIV Fusion Inhibitors/*pharmacology

• Source: Current opinion in investigational drugs (London, England : 2000) [Curr Opin Investig Drugs] 2006 Feb; Vol. 7 (2), pp. 106-8.Publisher: Thomson Reuters (Scientific) Ltd Country of Publication: England NLM ID: 100965718 Publication Model: Print Cited Medium: Print ISSN:

Record details

US FDA approves new class of HIV therapeutics.

• Authors : Robertson D

Subjects: Drug Approval*/Drug Approval*/Drug Approval*/*legislation & jurisprudence; Antiviral Agents/Antiviral Agents/Antiviral Agents/*classification ; Antiviral Agents/Antiviral Agents/Antiviral Agents/*therapeutic use

• Source: Nature biotechnology [Nat Biotechnol] 2003 May; Vol. 21 (5), pp. 470-1.Publisher: Nature America Publishing Country of Publication: United States NLM ID: 9604648 Publication Model: Print Cited Medium: Print ISSN:

Record details

Viral entry denied.

• Authors : Doms RW; Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, USA.

Subjects: HIV Fusion Inhibitors* ; Membrane Fusion* ; Receptors, Cell Surface*

• Source: The New England journal of medicine [N Engl J Med] 2004 Aug 19; Vol. 351 (8), pp. 743-4.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN:

Record details

The Low-Cost Compound Lignosulfonic Acid (LA) Exhibits Broad-Spectrum Anti-HIV and Anti-HSV Activity and Has Potential for Microbicidal Applications.

• Authors : Gordts SC; Rega Institute for Medical Research, University of Leuven, Leuven, Belgium.; Férir G

Subjects: Antiviral Agents/Antiviral Agents/Antiviral Agents/*pharmacology ; HIV Fusion Inhibitors/HIV Fusion Inhibitors/HIV Fusion Inhibitors/*pharmacology ; HIV-1/HIV-1/HIV-1/*drug effects

• Source: PloS one [PLoS One] 2015 Jul 01; Vol. 10 (7), pp. e0131219. Date of Electronic Publication: 2015 Jul 01 (Print Publication: 2015).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

Record details

Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK.

• Authors : Chong H; Qiu Z; Sun J

Subjects: Antiviral Agents/Antiviral Agents/Antiviral Agents/*pharmacology ; HIV Fusion Inhibitors/HIV Fusion Inhibitors/HIV Fusion Inhibitors/*pharmacology ; HIV-1/HIV-1/HIV-1/*drug effects

• Source: Retrovirology [Retrovirology] 2014 May 27; Vol. 11, pp. 40. Date of Electronic Publication: 2014 May 27.Publisher: BioMed Central Country of Publication: England NLM ID: 101216893 Publication Model: Electronic Cited Medium: Internet ISSN: 1742-4690

Record details

Selection and characterization of viruses resistant to the dual acting pyrimidinedione entry and non-nucleoside reverse transcriptase inhibitor IQP-0410.

• Authors : Buckheit RW Jr; ImQuest BioSciences, Inc., 7340 Executive Way, Frederick 21704, MD, USA. Electronic address: .; Watson Buckheit K

Subjects: Drug Resistance, Viral*; Antiviral Agents/Antiviral Agents/Antiviral Agents/*pharmacology ; HIV Fusion Inhibitors/HIV Fusion Inhibitors/HIV Fusion Inhibitors/*pharmacology

• Source: Antiviral research [Antiviral Res] 2013 Nov; Vol. 100 (2), pp. 382-91. Date of Electronic Publication: 2013 Sep 19.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8109699 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Agricola

Record details

Borean Pharma A/S Files Patent Application for Multimerized HIV Fusion Inhibitors.

• Source: Indian Patent News. 2011.

Record details